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ABSTRACT
The purpose of the present study was to determine the
I
neuronal circuitry responsible for 'K-opioid-mediated 
locomotion in preweanling rats. In two separate
experiments, 16-day-old rats were given bilateral
I
electrolytic lesions of the ventromedial thalamus and
, Isuperior colliculus and, two days later [i.e., postnatal
day (PD) 18] locomotor activity was assessed after a 
systemic injection of the K-opioid[receptor agonist U50,488. 
To ensure that lesions to the ventromedial thalamus orh
I
superior colliculus did not produce a general disruption of
non-opioid motor systems, the same'rats were retested on PD
i
I19 and given a systemic injection of- the dopamine receptor
iagonist R(-)-propylnorapomorphine (NPA). It was
i
hypothesized that bilateral lesions of the ventromedial
' ' 1
thalamus or superior colliculus would attenuate U50,488-
induced locomotor activity, while liaving no effect on NPA-
iinduced locomotor activity. As predicted, lesions to the
ventromedial thalamus and superioricolliculus partially
1
blocked U50,488's locomotor activating effects.
i
Importantly, these same lesions failed to disrupt the 
locomotor' activity produced by NPAj A third experiment was
iii
Iconducted to determine whether lesioning unrelated brain
structures would also attenuate U50,488 - induced locomotion.
For Experiment 3, the nucleus accumbens was lesioned
because it was expected that electrolytic lesions of this
brain region would not attenuate U50,488-induced locomotor
activity, while disrupting NPA-induced locomotion. The
I
results of Experiment 3 were surprising, because: 1)
nucleus accumbens lesions attenuated the locomotor activity
of U50,488-treated rats; and, 2) NPA-induced locomotor
activity was unaffected by nucleus ,accumbens lesions. It
is not clear why lesions to the nucleus accumbens affected
K-opioid-mediated locomotor activity, but one possibility is
that the nucleus accumbens is a component of the neural 
circuitry mediating U50,488-induced locomotion. Therefore, 
when these experiments are considered as a whole, this is
i
the first study to demonstrate that, the nigrothalamic and
nigrotectal pathways mediate, at least partially, the
U50,488-induced locomotor activity of preweanling rats.
I
iv
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CHAPTER ONE
BASAL GANGLIA1 4
Relevance,
The basal ganglia is a network of interconnected
regions in the brain that form a complex neuronal system
mediating a variety of behaviors, including motor movement, 
cognition, and emotional functioning (Hauber, 1998). 
Dysfunctions within the basal ganglia have been linked to a
number of psychiatric and neurological disorders. For
instance, Parkinson's disease, characterized by difficulty
Iin initiating movements, tremors, and rigidity, is
associated with degeneration of the nigrostriatal dopamine 
pathway (Carlsson, Lindqvist, & Magnusson, 1957; Cotzias, 
Papavasiliou, & Gellene, 1969; Fahn, 1989; Obeso, Olanow, &
Nutt, 2000). Basal ganglia dysfunction has also been
implicated in Huntington's disease (Haddad & Cummings, 
1997), obsessive-compulsive disorder (Miguel, Rauch, &
Jenike, 1997), tic disorder (Leckman, Peterson, Pauls, &
Cohen, 1997), dystonia (Cardoso & Jankovic, 1997), and 
dyskenisia (Cardoso & Jankovic, 1997).
Despite the fact that the neurological bases for some
of these disorders are well known (e.g., Parkinson's
1
disease), many disorders resulting 'from basal ganglia 
dysfunction are poorly understood. , Determining how the
basal ganglia functions is a first step towards
understanding the etiology of these disorders. Moreover, a
basic knowledge of basal ganglia anatomy is important for
developing potential pharmacotherapies. The goal of this
project is to characterize further 'how K-opioid receptors in
!
the basal ganglia modulate motor functioning, particularly
1
during early development. ;
Basal Ganglia Anatomy
Overview
The basal ganglia consists of a set of interconnected
subcortical nuclei (see Figure 1) found in thei
telencephalon, diencephalon, and midbrain (Albin, Young, &
i
Penney, 1989). The main input structure of the basal
ganglia is the striatum (corresponding to the caudate
I
nucleus and putamen in humans), which receives massive
glutaminergic (i.e., excitatory) afferent projections from!
all over the cortex (Ferino, Thierry, Saffroy, & Glowinski,
1987; Parent, 1990; Wilson, 1987)., The striatum, in turn,
sends projections to the substantia nigra, the main output
nuclei of the basal ganglia, via a direct (striatonigral)
2
II
I
pathway and an indirect (striatopaljlidal) pathway (Gerfen, 
1992b; Smith, Bevan, Shink, & Bolam, 1998). The substantia
I
nigra then sends its own output projections to thei
Ithalamus, superior colliculus, and pedunculopontine nucleus 
(Gerfen, 1992a; Gerfen, Staines, Arjbuthnott, & Fibiger,
, i
1982; Parent & Hazrati, 1995). 1
i
The three target projections of the substantia nigra
' Ipars reticulata (i.e., the thalamusi, superior colliculus,
and pedunculopontine nucleus) send iexcitatory (i.e.,
i
glutaminergic) projections to varidus brain regions.
i
First, the thalamus sends an excitatory projection back to
Ithe cortex and striatum (Mengual, de las Heras, Erro,
Lanciego, & Gimenez-Amaya, 1999) . iSecond, the superior
■ i
colliculus transmits an excitatory 'projection to the
thalamus and cortex (Benevento & Fallon, 1975; Binns, 1999;
Harting, Huerta, Frankfurter, Strominger, & Royce, 1980).
Third, the pedunculopontine nucleus sends a feedback 
projection to the substantia nigra pars compacts (Charara,
I
Smith, & Parent, 1996) and the subthalamic nucleus (Bevan &
Bolam, 1995; Lavoie & Parent, 1994)( .
Therefore, it should be clear,why the organization of
the basal ganglia has been described in terms of parallel 
loopings, in which distinct circuitries are formed between
3
Glutamate
Figure 1. Major efferent and afferent pathways of the 
basal ganglia. The striatum receives input from all over 
the cortex and sends projections to the substantia nigra, 
via a direct pathway and an indirect pathway.
G
lu
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4
the cortex, striatum, substantia nigra, and thalamic output
systems (Alexander & Crutcher, 199Q; Alexander, DeLong, &
Strick, 1986). Specifically, discrete cortical information
is cycled through regions of the basal ganglia and sent
back, via the thalamus, to discrete cortical areas, thereby
Iforming a circular loop between the cortex and the basal
ganglia. Five such parallel circuitries have been
identified: 1) motor; 2) oculomotor; 3) dorsolateral
Iprefrontal; 4) lateral orbitofrontal; and 5) anterior
cingulate (Alexander & Crutcher, 1990; Alexander et al.,
I
1986). Different functional roles.are thought to be
I
associated with each of these circhitries, and theyI
collectively comprise the diversity of behaviors associated
with the basal ganglia. ,
i
In summary, the basal ganglia'is a complex network of
interconnected brain regions that receives massive input
from all over the cortex. The major input structure is the 
striatum, which transmits cortical, information via a direct 
and indirect pathway down to the substantia nigra pars
reticulata, the main output structure of the basal ganglia.
Information is then relayed through the thalamus to several
regions of the cortex, thereby completing the cortical
loop.
5
Striatonigral and Striatopallidal Pathways
Excitatory input from the cortex is transmitted to the
substantia nigra pars reticulata through a direct
(striatonigral) pathway and an indirect (striatopallidal) 
pathway (Albin et al., 1989; Gerfen, 1992b). In the direct 
pathway, corticostriatal input is transmitted directly to 
the substantia nigra pars reticulata (see Figure 1).
Neurons which provide this input are GABAergic, but also
release two neuropeptides: dynorphin and substance P
(Gerfen & Young, 1988; Smith et al, 1998; Steiner &
Gerfen, 1998) .
i
In contrast, the indirect pathway sends cortical
I
information to the substantia nigra pars reticulata via an 
array of interconnections involving the globus pallidus and
subthalamic nucleus (see Figure 1) (Smith et al., 1998).
I
GABAergic neurons originating in the striatum, which 
express and release enkephalin and•substance P (Gerfen & 
Young, 1988; Steiner & Gerfen, 1998), first provide 
corticostriatal input to the globus pallidus. The globus 
pallidus then sends an inhibitory projection to the
subthalamic nucleus. Two output pathways leave the
subthalamic nucleus: an excitatory feedback circuit to the
6
globus pallidus and an excitatory connection to the
substantia nigra pars reticulata. [
Different dopamine receptors are associated with the
two striatal projections to the substantia nigra pars
I
reticulata (i.e., the direct and indirect pathways).
Striatonigral GABAergic neurons generally express dopamine
DI receptors, whereas striatopallidal GABAergic neurons
express dopamine D2 receptors (Gerfen, 1992b; Gerfen,
Engber, Mahan, Susel, Chase, Monsma, & Sibley, 1990;
Steiner & Gerfen, 1998). Only a small number of
striatonigral and striatopallidal neurons express both
dopamine receptor subtypes (Steiner & Gerfen, 1998) .
Nigrotectal and Nigrothalamic Pathways
i
The opioid rich substantia nigra pars reticulata
I
serves as the main output structure for the basal ganglia.
There are three prominent output pathways exiting the
substantia nigra pars reticulata, and they project to the
superior colliculus (nigrotectal pathway), thalamus
(nigrothalamic pathway), and pedunculopontine nucleus
(nigropedunculopontine pathway)(see Figure 1) (Deniau &
Chevalier, 1992; Gerfen, 1992b; Steiner & Gerfen, 1998).
Each of these output pathways are inhibitory, because the
i
neurons comprising these connections release GABA. In
7
fact, the classic view of basal ganglia functioning is that
these target regions are under tonic inhibition from the 
substantia nigra pars reticulata arid that the loss of this 
tonic inhibition results in basal ganglia-mediated behavior
(Albin et al., 1989; Chevalier & Deniau, 1990) . For
instance, unilateral microinjectioris of GABA into the
substantia nigra pars reticulata produces contralateral
circling, presumably by inhibiting .the inhibitory output
pathways of the substantia nigra pars reticulata, resulting
t
in a disinhibition of the superior 'colliculus and
ventromedial thalamus (Kaakkola & Kaariainen, 1980; Kamata,
Kameyama, Okuyama, Hashimoto, & Aihara, 1985).
Nigrostriatal Pathway
One of the major ascending dopaminergic projections in
the brain originates in the substantia nigra pars compacta
and terminates in the striatum (Cooper, Bloom, & Roth,
2003; Joel & Weiner, 2000). Interestingly, dopaminergic
input via the nigrostriatal tract differentially affects
the direct and indirect efferent pathways of the striatum
(see Figure 1). Specifically, dopaminergic input excites
the striatonigral (i.e., direct) pathway, and inhibits the
striatopallidal (i.e., indirect) pathway (Alexander &
Crutcher, 1990; Gerfen & Young, 1988). Thus, the role of
8
Idopamine within the striatum may be' to strengthen cortical 
input to the striatum by inhibiting the direct pathway and 
facilitating the indirect pathway (Alexander & Crutcher,
1990) .
The K-opioid receptor system modulates the activity of
dopamine neurons comprising the nigrostriatal pathway. For
example, K-opioid receptor stimulation in the substantia
nigra pars compacta decreases the firing rates of dopamine
neurons, thus attenuating dopamine 'release in the striatumI ■
(Walker, Thompson, Frascella, & Friederich, 1987) .
Similarly, at the terminal region of the nigrostriatal
pathway (i.e., the striatum), stimulation of presynaptic k-
opioid receptors inhibits the release of dopamine (Di
Chiara & Imperato, 1988; Werling, Frattali, Portoghese,
1
Takemori, & Cox, 1988; Zaratin & Clarke, 1994) . In
summary, dopaminergic activity within the nigrostriatal
pathway partially mediates motor functioning, and it is
clear that K-opioid receptors have a significant role in
modulating this effect.
Mesocortical and Mesolimbic Pathways
The second of the major ascending dopaminergic
pathways briginates in the ventraltegmental area (Oades &
9
Halliday, 1987) . These cell bodies' send prominent
projections to cortical and limbic .regions (Cooper et al.,
I
2003). The mesocortical pathway is comprised of dopamine
fibers projecting to various cortical structures, including 
the medial prefrontal cortex, cingulate cortex, and
entorhinal areas. In contrast, projections to various
limbic structures, such as the most ventral part of the
striatum (i.e., nucleus accumbens) and amygdala, constituteI
the mesolimbic pathway. ]
I
Dopaminergic activity within the mesolimbic pathway is
affected by |i- and K-opioid receptor activity (see Figure
I
2) . For instance, stimulating p.-opioid receptors in the
I
ventral tegmental area has the effect of inhibiting
GABAergic neurons that tonically inhibit dopamine
projections to the striatum (Di Chiara & Imperato, 1988;i
Spanagel, Herz, & Shippenberg, 1990; 1992). In other
words, jx-opioid agonists disinhibit neurons of the
mesolimbic pathway by inhibiting GABAergic activity within
I
the ventral tegmental area. In contrast, K-opioid receptor
stimulation inhibits dopaminergic activity. Specifically,
K-opioid receptor agonists decrease dopaminergic functioning
I
in the nucleus accumbens by directly inhibiting dopamine
10
Figure 2. Dopaminergic activity of the mesolimbic pathway 
is modulated by pi- and K-opioid receptor stimulation. 
Increased |i-opioid activity increases dopamine release in 
the nucleus accumbens by inhibiting GABAergic activity, 
whereas increased K-opioid stimulation decreases dopamine 
release in the nucleus accumbens.
release at the terminal button (Spanagel et al., 1990;
1992) . When considered together, it is clear that //- and K
opioid receptor activity has opposing actions on the 
mesolimbic pathway, with //-opioid receptor stimulation
11
indirectly enhancing neurotransmission, while K-opioid
receptor stimulation inhibits dopamine release within the
nucleus accumbens.
12
CHAPTER TWO
K-OPIOID RECEPTOR,SYSTEMS
Overview
I
K-Opioid receptor systems are involved in regulating
motor control within the basal ganglia. Dynorphin
peptides, the endogenous ligands that primarily bind to k-
opioid receptors (Chavkin, James, & Goldstein, 1982;
Corbett, Paterson, McKnight, Magnan, & Kosterlitz, 1982),
are present in high concentrations'in the substantia nigra
I
pars reticulata (Zamir, Palkovits,& Brownstein, 1983;
!•
1984). Dynorphin peptides are synthesized in cell bodies
located in the striatum and are ultimately released from
w ■ f
terminal fibers in the substantia nigra. These peptides
serve as neuromodulators, because dynorphin, applied
locally into the substantia nigra pars reticulata,
modulates the activity of GABAergic cells projecting to the
I
ventromedial thalamus and superior' colliculus (Lavin &
Garcia-Munoz, 1985; Robertson, Hommer, & Skirboll, 1987).
Dynorphin-induced modulation of these GABAergic output 
pathways produces robust contralateral circling in adult
rats (Friederich, Friederich, & Walker, 1987; Matsumoto,i
Lohof, Patrick, & Walker, 1988b; Morelli & Di Chiara,
13
1985). Hence, it is clear that K-opioid receptor systems
have an important role in regulating motor control.
K-Opioid Receptor Classification
Over the last two decades the presence and specificity
of K-opioid receptors have been determined. Specifically,
the existence of three K-opioid receptors have been
established: Kl, k2, and, more recently, k3 (Cheng, Roques,
Gacel, Huang, & Pasternak, 1992; Clark, Liu, Price, Hersh,
Edelson, & Pasternak, 1989; Fowler & Fraser, 1994; Leslie &
i
Loughlin,; 1994; Mansour, Burke, Pavlic, Akil, & Watson,
1996; Mansour, Fox, Akil, & Watson, 1995). The Kl-opioid
receptor subtype has a high affinity for the endogenous
I
peptide dynorphin A and exogenous arylacetamide drugs such
as U50,488 and U69,593 (Leslie & Loughlin, 1994; Unterwald,
Knapp, & Zukin, 1991). The K2-opioid receptor has
I
considerable affinity for dynorphin A and other endogenous
opioid peptides (e.g., P-endorphin), as well as for
exogenous compounds such as diprenorphine,
ethylketo'cyclazocine, and bremazocine (Leslie & Loughlin,
1994). Because the k3-opioid receptor was discovered
recently, less is known about the affinity of endogenous
14
peptides for this receptor subtype. However, the exogenous 
compound naloxone benzoylhydrazone has been Identified as
having a high affinity for k3-opioid receptors (Cheng et
al., 1992; Clark et al., 1989).
K-Opioid Receptor Distribution
Adult Brain
Localization of Kl- and K2-opipid receptors in the
adult rat brain has been well established, with k2-opioid
receptors being more abundant than Kl-opioid receptors
(Unterwald et al., 1991; Zukin, Eghbali, Olive, Unterwald,
& Tempel, 1988) . Kl-opioid receptors are found in the
caudate-putamen (i.e., striatum), nucleus accumbens, medial
Inucleus of the thalamus, superior colliculus, substantia
nigra pars reticulata, ventral tegmental area, and
hypothalamus (Mansour et al. , 1996;: Unterwald et al. ,
I
1991). k2-opioid receptors are found throughout the brain,
including several regions of the thalamus, inferior
colliculus, amygdala, olfactory tubercles, endopiriform
nucleus, claustrum, substantia nigra, nucleus accumbens,
and striatum (Unterwald et al., 1991; Zukin et al., 1988).
Relatively few studies have examined the distribution of k3-
15
opioid receptors, although binding sites for this receptor
have been recognized in the hypothalamus, thalamus,
striatum, and midbrain (Cheng et al., 1992) .
Ontogeny j
The ontogenesis of K-opioid repeptors has been
I
examined, although the development of individual K-opioid
receptor subtypes has received minimal empirical study (but
see Allerton, Smith, Hunter, Hill, & Hughes, 1989; Kitchen,
receptors begin to emerge
day (ED) 14.5 and
il ED 18.5, where they
Loughlin, 1994). After
Kelly, & Viveros, 1990) . K-Opioid
in rat brain as early as embryonic
continue to increase in density unt
remain stable until birth (Leslie
birth, the developmental pattern of K-opioid receptors is
more controversial. For example, one study has reported
that adult-like K-opioid receptor concentrations are
attained sometime between postnatal day (PD) 7 and PD 14
(Petrillo, Tavani, Verotta, Robson, & Kosterlitz, 1987).
In contrast, Spain and colleagues report a more complex
pattern of development, as they found that K-opioid receptor
densities simultaneously increase in hindbrain and decrease 
in forebrain across the first postnatal week (Spain, Roth,
& Coscia, 1985). This effect .is reversed during the second
16
postnatal week, with forebrain K-opioid receptor densities
increasing and hindbrain K-opioid peceptor densities
decreasing. Reductions in hindbrain receptor densities are
attributed to a lack of K-opioid receptor binding sites in
I
the cerebellum, a structure which undergoes substantial
growth during this time (Spain et al., 1985).I
Age-dependent changes in K-opioid receptor densities
have not been ascribed to specific brain regions, because
I
ontogenetic studies have primarily'focused on K-opioid
receptor binding in whole brain or jspinal cord (see
Allerton et al., 1989; Attali, Saya, & Vogel, 1990;
Petrillo et al., 1987; Spain et al., 1985). Nevertheless,
receptor autoradiography has revealed that by PD 20 K-opioid
receptors are present in the striatum, nucleus accumbens,
olfactory tubercle, hypothalamus, amygdala, and thalamic
regions (Kornblum, Hurlbut, & Leslie, 1987) .
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CHAPTER THREE
BEHAVIORAL EFFECTS OF K-OPIOID
RECEPTOR STIMULATION
i
Adult Studies
i
Behavioral effects of K-opioid receptor stimulation in
adult rats have been well characterized. Systemic
injections with various K-opioid receptor agonists (e.g.,
U50,488, PD 117302, and enadoline) decrease the locomotor
activity, rearing, and grooming of adult rats and mice
(Castellano & Pavone, 1987; Jackson & Cooper, 1988;
Leighton, Johnson, Meecham, Hill, & Hughes, 1987; Leyton &
Stewart, 1992; Ukai & Kameyama, 1985). Decreased
I
Ibehavioral activity can be reversed by the highly selective i
i
K-opioid receptor antagonist nor-binaltorphimine (nor-BNI)
(Portoghese, Lipkowski, & Takemori,1 1987; Takemori, Ho,
Naeseth, & Portoghese, 1988), indicating that K-opioid
I
receptors mediate this behavioral effect (Kuzmin, Sandin,
Terenius, & Ogren, 2000). The actions of K-opioid.receptor
agonists are dose-dependent, because lower doses (0.1-1.0 
mg/kg) of U50,488 have no effect on behavioral activity,
while higher doses (5.0-10.0 mg/kg) significantly reduce
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locomotion, rearing, and grooming (Leighton et al., 1987;
Leyton & Stewart, 1992; Ukai & Kameyama, 1985).
Two exceptions to this pattern: of results have been
reported.1 First, Kuzmin and colleagues demonstrated that
non-habitiiated mice (i.e., mice that had not been
acclimated to the testing chamber) 'exhibited enhanced
locomotion 40 min after being given a low dose (1.25 or 2.5 
mg/kg) of U50,488 (Kuzmin et al. , 2000). In contrast, mice
I
allowed to explore the testing chamber 30 min before
I
receiving an injection of U50,488, .failed to exhibit the
I
same enhanced locomotor response, 'importantly, systemic
I
injections of nor-BNI failed to block the increased
locomotor activity exhibited by non-habituated mice,
indicating that this was not a K-opioid-mediated effect
(Kuzmin et al., 2000).
I
Second, systemic injections of K-opioid receptor
agonists have different behavioral actions depending on the
species being studied. Specifically, adult hamsters show
enhanced locomotor activity after a systemic injection of a
low dose of U50,488 (1.0 mg/kg) (Schnur & Walker, 1990). A 
systemic injection of a high dose (10 mg/kg) of U50,488,
however, decreased the locomotor activity of hamsters.
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Thus, both adult hamsters and adult' rats show decreased
locomotor activity after systemic administration of a K- 
opioid receptor agonist. '
It is unlikely that the U50,488-induced locomotor
1.
activity of adult hamsters was a result of a non-opioid
1
effect, because the increased locomotion was attenuated by
a systemic injection of naloxone (a non-specific opioid 
receptor antagonist). Rather, Schnur and Walker (1990)
suggest that regional differences in the densities of k- 
opioid receptors may account for tbe different behavioral 
patterns exhibited by U50,488-treated rats and hamsters.
More precisely, adult hamsters have comparatively greater
densities of K-opioid receptors in'the substantia nigra pars
reticulata than adult rats. Importantly, adult rats show
iincreased locomotor activity when the substantia nigra pars
reticulata is stimulated by microinjections of K-opioid
receptor agonists (Friederich et al., 1987; Matsumoto et
al., 1988b). Thus, it is probable that low doses of
U50,488 increase the locomotor activity of adult hamsters
by preferentially stimulating K-opioid receptors in the
substantia nigra pars reticulata. 1
I
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In sum, systemic administration of K-opioid receptor
agonists to adult rats and mice typically results in
reduced behavioral activity. Interestingly, systemically
administering a low dose of a K-opioid receptor agonist
enhances the locomotor activity of'adult hamsters. The
latter effect is probably caused by preferential
stimulation of K-opioid receptors in the substantia nigra
pars reticulata, because adult hamsters have a greater
abundance of K-opioid receptors in this area compared to
adult rats (Schnur & Walker, 1990) ■.
The ability of K-opioid receptor agonists to suppress
the locomotor activity of adult rats is probably due to
decreased dopaminergic neurotransmission. Specifically,
when U50,488 is given systemically1, decreased dopamine
release is evident in the nucleus accumbens and striatum
(Di Chiara & Imperato, 1988; Maisonneuve, Archer, & Glick,
1994; Zaratin & Clarke, 1994). This decrease in
dopaminergic activity may be responsible for U50,488's
locomotor inhibiting effects. Consistent with this
hypothesis, increased dopamine neurotransmission within the
I
nucleus accumbens and striatum, caused by microinjecting
I
dopamine agonists into these brain regions, enhances the
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locomotor activity of adult rats (Essman, McGonigle, &
Lucki, 1993; Kelley, Lang, & Gauthier, 1988).
The means by which K-opioid receptor agonists modulate
dopaminergic neurotransmission are .well known, as systemic
administration of a K-opioid receptor agonist decreases
dopamine activity via two independent mechanisms. One
mechanism involves stimulation of presynaptic K-opioid
receptors located on dopamine terminals in the nucleus
accumbens and striatum. Local application of U50,488 into
these regions directly inhibits the release of dopamine
(see Figure 2), an effect that can be blocked by K-opioid
receptor antagonists (Werling et al., 1988).
A second mechanism involves decreasing the neuronal
activity of the nigrostriatal pathway. Specifically, the
firing rates of dopaminergic nigrostriatal cells are
inhibited when U50,488 is either administered systemically
or microinjected into the substantia nigra pars reticulata.
This reduction in neuronal firing rates causes decreased
dopamine release in the striatum (Thompson & Walker, 1990;
Walker et al., 1987; but see Lavin' & Garcia-Munoz, 1985).
Regardless of the mechanism (i.e.f| stimulating presynaptic
K-opioid receptors or reducing neuronal firing rates), k-
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opioid receptor agonists reduce the locomotion of adult
rats by decreasing dopamine transmission in the striatum
and/or nucleus accumbens.
In contrast to systemic administration, microinjecting
K-opioid receptor agonists into the substantia nigra pars
reticulata of adult rats produces a dramatically different
behavioral effect. Specifically, unilateral infusion of
U50,488 into the substantia nigra pars reticulata results
in robust contralateral circling (lyiatsumoto, Brinsfield,
Patrick, & Walker, 1988a; Thompson & Walker, 1992) .
Similar effects are observed when various dynorphin
peptides (i.e., endogenous ligandsJfor K-opioid receptors) 
are administered into the substantia nigra pars reticulata.
' I
For instance, unilateral microinjections of dynorphin A(1_8),
dynorphin A(i_i7), or dynorphin B into the substantia nigra 
pars reticulata of adult rats, produces robust 
contralateral circling (Friederich;et al., 1987; Herrera- 
Marschitz', Christensson-Nylander, Sharp, Staines, Reid, 
Hokfelt, Terenius, & Ungerstedt, 1986; Herrera-Marschitz, 
Hokfelt, Ungerstedt, & Terenius, 1983; Herrera-Marschitz,
Hokfelt, Ungerstedt, Terenius, & Goldstein, 1984; Matsumoto
et al., 1988b; Morelli & Di Chiara, 1985). The finding
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that route of administration (i.e., systemic vs.
intracranial) produces dramatically different behavioral 
effects in adult rats, suggests that K-opioid receptor
stimulation has two distinct actions: an inhibitory and a
stimulatory effect on locomotor activity.
One possibility is that the locomotor stimulating
I
effects of K-opioid receptor agonists are caused by
increased dopamine neurotransmission in the nigrostriatal
and/or mesolimbic pathways. This explanation seems
unlikely for three reasons. First,( K-opioid receptor
stimulation decreases, rather than 1 increases, dopaminergic
I
neurotransmission by diminishing the firing rate of
substantia nigra pars compacta dopamine neurons projecting
I
to the striatum (Walker et al., 1987). Second, lesions of
the nigrostriatal pathway fail to inhibit the contralateral
I
circling produced by microinjecting U50,488 into the
substantia nigra pars reticulata (1986; Herrera-Marschitz
et al., T984; Morelli & Di Chiara, 1985). Third, lesions
I
of the striatum potentiate, rather.than attenuate, K-opioid 
induced circling (1986; Herrera-Marschitz et al., 1984).
When considered together, it appears that K-opioid-induced
locomotor activity is not mediated by dopaminergic systems.
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Rather, there is evidence suggesting that the enhanced
motor movement induced by K-opioid receptor stimulation of
the substantia nigra pars reticulata is a result of
disinhibiting GABAergic output neurons originating in the 
substantia nigra pars reticulata and projecting to the
ventromedial thalamus and superior colliculus (Thompson &
Walker, 1992). More precisely, under normal conditions the
substantia nigra tonically inhibits the motor circuits of 
the superior colliculus and the ventromedial thalamus via
GABAergic output fibers (see Figure 3A). K-Opioid receptor
stimulation in the substantia nigra pars reticulata
inhibits these GABAergic output neurons and keeps them from
inhibiting the ventromedial thalamus and superior
colliculus (see Figure 3B). Thus, through the process of
disinhibition, K-opioid receptor agonists administered into
the substantia nigra pars reticulata cause increased motor
movement by removing the superior colliculus and
ventromedial thalamus from inhibition.
When considered together, it is evident that K-opioid
receptor stimulation has two different, but concurrent,
actions in the adult rat. First, K-opioid receptor agonists
inhibit locomotor activity by decreasing dopamine release
25
PREMOTOR AREASSTRIATUM
Figure 3. Representation of the normal activity of 
substantia nigra pars reticulata neurons. During normal 
conditions, the substantia nigra pars reticulata inhibits 
the thalamus and superior colliculus (Upper diagram). 
Dynorphin stimulates K-opioid receptors located on the 
GABAergic output projections of the substantia nigra pars 
reticulata. The dynorphin inhibits these GABA neurons, 
thus disinhibiting neurons in the ventromedial thalamus 
and superior colliculus (lower diagram).
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in the nucleus accumbens and striatum. Second, K-opioid
receptor agonists stimulate locomotor activity by
disinhibiting the GABAergic output neurons of the
nigrothalamic and nigrotectal pathways. Apparently, the
locomotor inhibiting effects of K-opioid receptor agonists
(mediated by the dopaminergic nigrostriatal and/or
i
mesolimbic pathways), overwhelm the locomotor activating
effects of K-opioid receptor agonists (mediated by GABAergic
nigrotectal and nigrothalamic pathways). This conclusion
is based on the finding that systemic administration of
U50,488 decreases the locomotor activity of adult rats.
Ontogenetic Studies
K-Opioid receptor stimulation.produces a dramatically
different effect in preweanling rats when compared to
adults. Specifically, increased locomotor activity is 
evident after systemic injections of U50,488 or enadoline
in 3-, 5-, 10-, or 17-day-old rats (Bolanos, Garmsen,
Clair, & McDougall, 1996; Collins, Zavala, Ingersoll, Duke,
Crawford, & McDougall, 1998; Duke, Meier, Bolanos,
Crawford, & McDougall, 1997; Jackson & Kitchen, 1989;
McDougall, Rodarte-Freeman, & Nazarian, 1999; McLaughlin,
JTao, & Abood, 1995). The longevity of this effect is
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restricted to the preweanling period, however, because 35-
day-old rats, like adult rats, do not exhibit enhanced
motor movement after a systemic injection of U50,488
I
(Bolanos et al., 1996). U50,488's and enadoline's actions
are mediated by K-opioid receptors, since systemic
injections of nor-BNI block U50,488- and enadoline-induced
locomotor activity in 3- and 18-day-old rats (Collins,
I
Zavala, Nazarian, & McDougall, 2000; McLaughlin et al.,
1995).
At present, it is not known why systemic
administration of a K-opioid receptor agonist enhances the
locomotor activity of preweanling rats. One possibility is
that K-opioid receptor agonists activate the nigrostriatal
or mesolimbic dopamine pathways. This seems unlikely,
however, because decreasing dopamine transmission with d'-
methyl-DL-p-tyrosine (AMPT) fails to attenuate U50,488-
induced locomotor activity of preweanling rats (McDougall,
Garmsen, Meier, & Crawford, 1997). Importantly, depleting
dopamine with AMPT is effective at' reversing the locomotor 
activity induced by amphetamine (an indirect dopamine
agonist). Therefore, it appears that the K-opioid-induced
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locomotor activity of preweanling rats is not mediated
through dopaminergic mechanisms.
A second possibility is that K-opioid receptors in the
substantia nigra pars reticulata mediate the locomotor
activating effects of U50,488. This explanation has
received empirical support, because microinjecting UFO,488
into the substantia nigra pars reticulata causes a dose-
dependent increase in the locomotor activity of 18-day-old
rats (Collins et al., 2000). Importantly, this U50,488-
Iinduced locomotor activity was blocked by both systemic and
intra-nigral injections of nor-BNI-, but not by infusions of
nor-BNI into the dorsal striatum (Collins et al., 2000).
When considered together, it is clear that young rats
exhibit robust motor responses after systemic or intra-
nigral injections of a K-opioid receptor agonist. It is
also clear that K-opioid receptors' within the substantia
nigra pars reticulata mediate this psychopharmacological
effect. i
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CHAPTER FOUR
SUMMARY AND HYPOTHESES
Summary and Purpose
Stimulation of K-opioid receptors by systemicI
injections of U50,488 decreases the locomotor activity of
adult rats. This effect is probably caused by decreased
dopaminergic neurotransmission in the nucleus accumbens and
striatum. In contrast, stimulation of K-opioid receptors in
the substantia nigra pars reticulata produces enhanced
I
motor movement in adult rats. For instance, unilateralI
microinjections of U50,488 or dynorphin peptides (e.g.,
dynorphin A(i_8), dynorphin A(i_i7), o,r dynorphin B) into the
i
substantia nigra pars reticulata causes contralateral 
circling (Friederich et al. , 1987;' Herrera-Marschitz et al. ,
1983; 1984; Matsumoto et al., 1988a; Morelli & Di Chiara,
1985). K-Opioid-induced circling in adult rats is a result
i
of disinhibiting the nigrotectal and nigrothalamic premotor
pathways (Thompson & Walker, 1992),. In summary, K-opioid
receptor agonists differentially affect the locomotor
I
activity of adult rats, depending on what brain areas are
affected: Systemic injections of U50,488 decrease locomotor 
activity in adult rats, while microinjecting U50,488 into
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Ithe substantia nigra pars reticulata enhances motoric
movement.
Unlike in the adult rat, systemic administration of a
K-opioid receptor agonist increases the locomotor activity
of preweanling rats. For instance, systemic injections of
U50,488 enhances the motor responses of 3-, 5-, 10-, or 17-
day-old rats (Bolanos et al., 1996; Collins et al., 1998;
Duke et al., 1997; Jackson & Kitchen, 1989; McDougall et
al., 1999; McLaughlin et al., 1995). The substantia nigra
pars reticulata is the neuroanatomical locus for this k-
opioid-mediated effect, since intranigral injections of
U50,488 cause a dose-dependent increase in locomotor
activity (Collins et al., 2000) . Until now, however, no
I
study has determined which nigral output pathway mediates
U50,488-induced locomotor activity,in preweanling rats.
It is possible that U50,488 enhances the locomotor
activity of preweanling rats by disinhibiting GABAergic
projections from the substantia nigra pars reticulata toi
the ventromedial thalamus and superior colliculus. The
only support for this hypothesis comes from a non-
ontogenetic study which showed that the U50,488-induced
contralateral circling of adult rats is attenuated by
i
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Ilesions to the ventromedial thalamus and superior
colliculus (Thompson & Walker, 1992). . If a similar
mechanism mediates the K-opioid-induced locomotor activity
I
of preweanling rats, then lesions to the ventromedial
thalamus and superior colliculus should disrupt U50,488's
locomotor activating effect. Alternatively, if other
nigral output pathways are responsible for K-opioid-mediated
motor movement, then lesions to the ventromedial thalamus
and superior colliculus should be ineffective at reducing 
U50,488-induced locomotor activity!
The purpose of this thesis, therefore, was to
I
determine the neuronal circuitry mediating U50,488-induced
locomotion in preweanling rats. To this end, preweanling
rats received bilateral electrolytic lesions of the
ventromedial thalamus or superior colliculus and, two days
later, the same rats received a challenge injection of
U50,488. It was predicted that bilateral lesions of the
ventromedial thalamus or superior colliculus would
attenuate the U50,488-induced locomotor activity of 18-day-
old rats.
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' Experimental Controls
j I
When! interpreting the effects(of brain lesions on
drug-induced changes in locomotor activity it is important
i 1 ' • ’
to determine whether the lesion caused a generalized
disruption of normal motoric functioning. If motor ability
was compromised, interpretation of I drug-induced behavioral
' I
changes would be problematic. Thus, in the present study, i .
two measures were taken to ensure trhat lesions to thei 1
' : Iventromedial thalamus and superior|colliculus did not
I
produce a general deficit in motorifunctioning.
I
First, baseline levels of locomotor activity were
assessed prior to U50,488 injections to determine whether
J i - ;
the lesions caused a change in.basal activity. Second, to
ensure that the functioning of non-opioid motor systems
! . iwere not affected by lesions of the nigrothalamic and
Ii i . *;nigrotectal pathways, drug-induced changes in locomotor
; ' I
activity were assessed after a systemic injection of the
dopamine agonist R(-)-propylnorapomorphine (NPA). When
, i •
given sys'temically, NPA increases the locomotor activity of
. ' ' i
rats via dopaminergic mechanisms (Duke et al., 1997;
i !: iKafetzopoplos, 1986; Kelly & Roberts, 1983) . Thus, NPA-
! .: 1
induced increases in locomotor activity were expected to be
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largely unaffected by lesions of the ventromedial thalamus
and superior colliculus.
For this study, it was also important to determine the
specificity of brain lesions. In other words, it was 
necessary to provide an anatomical control to determine
whether lesioning unrelated brain structures also reduces
U50,488-induced locomotion. Consequently, an additional
experiment was conducted where separate groups of rats were
given bilateral electrolytic lesions of the nucleus
accumbens and tested with U50,488. The nucleus accumbens •
is not thought to mediate U50,488-induced locomotor
activity, so lesioning this structure was not expected to
impact U50,488's behavioral effects. Thus, it was
predicted that bilateral lesions of the nucleus accumbens
would fail to attenuate the U50,488-induced locomotor
activity of 18-day-old rats. Conversely, lesions to the
nucleus accumbens were expected to disrupt NPA-induced
locomotor activity, since NPA's actions are known.to be
mediated by the mesolimbic pathway (Kafetzopoulos, 1986;
Kelly & Roberts, 1983).
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Hypotheses
In summary, three separate experiments were conducted.
In the first experiment, rats received bilateral lesions of
the ventromedial thalamus and locomotor activity was
assessed after systemic injections of U50,488 or NPA. It
was hypothesized that: 1) lesions of the ventromedial
thalamus would attenuate U50,488-induced locomotor
activity; and 2) lesions of the ventromedial thalamus would
fail to affect NPA-induced locomotion. In the second
experiment, rats received bilateral lesions of the superior
colliculus and locomotor activity Was assessed after
systemic injections of U50,488 or NPA. It was hypothesized
that: 1) lesions of the superior colliculus would attenuate
U50,488-induced locomotor activity; and 2) lesions of the
superior colliculus would have no effect on NPA-induced
locomotion. In the third experiment, rats received
bilateral lesions of the nucleus accumbens and locomotor
activity was assessed after systemic injections of U50,488
or NPA. It was hypothesized that:11) lesions of the
nucleus accumbens would fail to attenuate U50,488-induced 
locomotor activity; and 2) lesions!of the nucleus accumbens 
would disrupt NPA-induced locomotion.
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CHAPTER FIVE
GENERAL METHODS
Subj ects i
Subjects were 84 male and female rats of Sprague-
Dawley descent (Harlan) born and raised at California State
University, San Bernardino. Litters were culled to 10 rat
pups by PD 3. Pups remained with the dam until time of
surgery. At PD 16, rats were randomly assigned to groups.
No more than one rat from each litter was placed into a
particular group. Effort was made to ensure an equal
number of male and female rats in each group. The colony
room was maintained at 22°C-24°C and kept on a 24 h
I
light/dark cycle (lights on at 6:00 am).
Apparatus
Behavioral testing was done in commercially available
(Coulbourn Instruments, Allentown, PA) activity monitoring
chambers (25.5 x 25.5 x 41 cm), consisting of Plexiglas
walls, a plastic removable floor, and an open top. Each
chamber included an X—Y photobeam array, with 16 photocells
and detectors, which were used to determine distance
traveled (a measure of horizontal locomotor activity).
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Drugs
(±)- trans-U50,488 methanesulfonate,(U50,488) and R(-)-
propylnorapomorphine hydrochloride1 (NPA) were obtained from 
Sigma (St. Louis, MO) and dissolved in distilled water.
Both U50,488 and NPA were injected, intraperitoneally (ip)
at a volume of 5 ml/kg.
Surgery
On PD 16, rats were anesthetized with a solution of
ketamine and xylazine (Sigma) and placed on a Cunningham
Neonatal Rat Adapter attached to a1 standard Kopf
stereotaxic apparatus (Cunningham & McKay, 1993) . A single
incision was made mid-sagitally al.ong the skull and the
skin was retracted. Separate groups of rats were then
given bilateral electrolytic lesions of the ventromedial
!
thalamus (Experiment 1), superior colliculus (ExperimentI
2), or nucleus accumbens (Experiment 3).
IElectrolytic lesions were made by passing anodal
I
constant current (1.0 mA, Grass DC Lesion Maker) through a
Teflon-insulated tungsten electrode (0.2 mm in diameter, 
A.M. Systems) that was exposed 1.6 mm at the tip. For the
ventromedial thalamic lesions the electrode was lowered and
left in place for 20 s, with current applied at the
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(following coordinates: +3.5 mm anteroposterior (AP) , ±0.5
mm mediolateral (ML), -4.0 mm dorsoventral (DV). In order
to create a complete lesion of the•superior colliculus two
electrode placements were necessary. For the superiorI
colliculus, the electrode was left,in place for 55 s while
current was being applied. The coordinates for the
superior colliculus lesions were: 40.4 mm AP, +1.5 mm ML, -
7.0 mm DV; and -0.6 mm AP, +1.5 ML, -7.0 DV. Lesions of
the nucleus accumbens required only one electrode placement
I
at -6.2 mm AP, +2.2 mm ML, -6.8 mm, DV. For the nucleus
I
accumbens lesion, current was applied for 30 s. In all
cases, coordinates were obtained ftom the developing rat
brain atlas of Sherwood and Timira's (1970) . An equal
I
number of rats from each litter were given bilateral sham-
lesions using procedures identical to those described
above, except that no current was 'applied. After surgery,
rats were allowed to recover in a temperature controlled
(30°C) chamber. After becoming fully responsive, rats were
placed back with the dam and tested 48 hr and 72 hr later.
Histology
Immediately after behavioral assessment, rats were
I
given an overdose of Nembutal and.perfused intracardially
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with saline followed by a 4% paraformaldehyde solution.
After a 7-day postfixation period, coronal sections were
taken from each brain using a Vibratome 1000 sectioning
apparatus (Ted Pella, Redding, CA). Sections were stained
with thionin, coverslipped, and underwent lesion site
verification using a microscope. Rats that had partial or
inadequate lesions were removed and replaced.
Statistical Analyses
Analysis of Variance (ANOVA) for repeated measures (5
min time blocks) was used for statistical analysis of
distance traveled data. The first three time blocks,
I
consisting of baseline locomotor assessment, were analyzed 
separately from the last nine timej blocks. Baseline 
locomotor activity was not different between sham and
lesioned rats in any of the expieriments. Body weight data
were analyzed using a 3 x 2 (day x[ lesion) repeated measures
ANOVA. To control for litter effects, one rat from each
litter was placed into a particular group. Litter was then
used as the unit of analysis for the statistical analyses.
With this statistical model each litter, rather than each
rat, was treated as an independent observation (Zorrilla,
1997). Sex differences were assessed using separate
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between-spbject ANOVAs. No,.’sex differences were found, and
I t.
thus the data was presented collapsed’ acrossed male and
! • ■ - ; :
female rats. Post hoc analyses ofjsimple main effects and
I 1
interactions were made using TukeyiHSD tests ' (p < 0.05) .
I !
For the first and second experiment, in addition to
comparing group differences, the correlation between
! i
percent ofc brain area lesioned and 1U50,,488-induced
j I
locomotor; activity was determined using the Pearson
tI ;
product-moment correlation (r). For these correlations,
i !
j (rats that| had improper lesions were included in the 
I i ’
analyses.] It was predicted that there would be a negative
correlation between lesion size and U50,488-induced
locomotor! activity, with decreased,locomotor activity being
.! ; ■ ' '
exhibited! by U50,488-treated rats as the percentage of
!
; i
brain area lesioned increased. I
!
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CHAPTER SIX
EXPERIMENT ONE
Overview,
The first experiment was conducted to determine
whether U50,488-induced locomotor activity was attenuated
by lesions of the ventromedial thalamus. A second purpose
of Experiment 1 was to determine whether lesions of the
ventromedial thalamus produced a general decrease in
I
motoric functioning. Consequently,1 rats were also injectedi
with the dopamine receptor agonist NPA. NPA increases
locomotor activity in rats by stimulating dopamine
receptors in the nucleus accumbens and striatum
(Kafetzopoulos, 1986; Kelly & Roberts, 1983), and not by
altering the functioning of nigral output pathways
projecting to the ventromedial thalamus. Therefore, it was
predicted that bilateral lesions of the ventromedial
thalamus would attenuate U50,488's locomotor activating
effects, but have no effect on NPA-'induced locomotor
activity.
Method
A total of 28 rats (n = 7 per group) received 
bilateral electrolytic lesions or sham lesions of the
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ventromedial thalamus on PD 16. On PD 18, these rats were
singly placed in the testing chambers and baseline
I
locomotor activity was assessed for 15 min. Sham- and
ventromedial thalamus-lesioned rats were then injected with
saline or U50,488 (5.0 mg/kg, ip) and returned to the
testing chambers for an additional 45 min. This dose of
U50,488 was chosen because previous studies have shown that 
5.0 mg/kg U50,488 reliably produces robust locomotor
activity in preweanling rats (Collins et al., 1998; 2000). 
Following behavioral testing,1 rats were returned to
their home cage and placed back with the dam. After an
additional 24 hr, rats were retested as described above,
except that half of the rats (counterbalanced for previous
drug treatment) were given a single injection of saline and
the other half an injection of NPA (0.01 mg/kg, ip). This
dose of NPA was chosen because it has been shown that 0.01
mg/kg NPA produces robust locomotor activity in preweanling
I
rats (Duke et al., 1997).
Results'
Histology
A representative lesion of the ventromedial thalamus
is shown in Figure 4. Rats that did not have at least 75%
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II
Figure 4. Image of a thionin-stained section indicating 
the damage produced by an electrolytic lesion of the 
ventromedial thalamus on postnatal1 day 16.
j
of the ventromedial thalamus destroyed on each hemisphere
were removed from the experiment and replaced.
I I
Body Weight
The.body weights of sham- and ventromedial thalamus-j
lesioned rats are shown in Figure 5 (left panel). Rats in
!
Experiment 1 showed an increase in body weight across the
I
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E
IExperiment 1 Experiments Experiments
Figure 5. Mean body weight (+SEM) i of rats (n = 7-9) from 
Experiments 1, 2, and 3. Regardless of experiment, no body 
weight differences were found betwfeen sham or lesioned rats
(£ > 0.05). 1
i
I
i
four days of the experiment [day main effect, F(2, 52) =1
I
50.49, p< 0.001}. Importantly, body weights of the sham
I
and ventromedial thalamus-lesioned' rats did not differ.
i ■ 1
iLocomotor Activity
I I
Distance traveled (i.e., locomotor activity) data for
; !
sham- and ventromedial thalamus-lesioned rats given
systemic injections of U50,488 and NPA are presented in
i
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Figure 6. Overall, 18-day-old rats injected with U50,488
(5 mg/kg, ip) exhibited more locomotor activity than
saline-treated rats [agonist main effect, F(l, 6) = 139.79,
p < 0.001; agonist x time interaction, F(8, 48) = 19.86, p <
0.001]. Bilateral lesions of the ventromedial thalamus
attenuated the locomotor activity of 18-day-old rats
injected with U50,488 [lesion x agonist interaction, F(l, 6)
= 41.53, p < 0.001; lesion x agonist x time interaction,
F(8, 48) = 2.79, p < 0.05]. Specifically, sham-lesioned
Irats given U50,488 exhibited more locomotor activity on
time blocks 5-12 than ventromedial thalamus-lesioned rats
given U50,488 (see upper graph, Figure 6). Bilateral
lesions of the ventromedial thalamus did not completely
I
block U50,488- induced locomotor activity, however, since
ventromedial thalamus-lesioned rats exhibited significantly
more locomotor activity on time blocks 7-12 compared to
saline-treated rats. Thus, lesions to the ventromedial
i
thalamus result in a disruption of U50,488-induced
locomotor activity. The extent of' damage to the
ventromedial thalamus was negatively correlated with the
amount of locomotor activity exhibited after systemic
injections of U50,488 (data not shown) [r(14) = —0.37], but
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Ventromedial Thalamus
Figure 6. Mean distance traveled (+SEM) of rats that had 
received sham or electrolytic lesions of the ventromedial 
thalamus on postnatal day (PD) 16. On PD 18, rats (n = 7) 
were injected with saline or U50,488 (5 mg/kg, ip) 15 min 
into the behavioral testing session (indicated by the 
dashed line). On PD 19 the same fats were injected with 
saline or NPA (0.01 mg/kg, ip) 15 min into the behavioral 
testing session (indicated by the dashed line). (a)
Significantly different from the Sham-Saline group (open 
symbols). (b) Significantly different from the Lesion-
1150,488 group (filled square).
I
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this effect did not reach statistical significance (p >
0.05).
On the following day (i.e., PD 19), the same rats were
injected with saline or 0.01 mg/kg NPA (see lower graph, 
Figure 6). Rats given systemic injections of NPA exhibited
greater locomotor activity on time blocks 5-10 compared to
rats injected with saline [agonist1 main effect, F(l, 6) =
37.88, p < 0.001; agonist x time interaction, F(8, 48) = 
28.98, p < 0.001]. Importantly, lesions of the
ventromedial thalamus failed to affect NPA-induced
locomotor activity, because sham- and ventromedial
thalamus-lesioned rats responded similarly to a systemic
injection of NPA.
I
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CHAPTER SEVEN
EXPERIMENT TWO
Overview
In the second experiment, the'ability of superior
colliculus lesions to attenuate U50,488-induced locomotor
activity was assessed. As in Experiment 1, rats were
retested with NPA to determine whether superior colliculus
lesions cause a general decrease in motor functioning. It
was predicted that bilateral lesions of the superior
colliculus would attenuate U50,488's locomotor activating
effects, while having no effect on NPA-induced locomotion.
Method ,
A total of 28 rats (n = 7 per1group) received 
bilateral electrolytic lesions or sham lesions of the
superior colliculus on PD 16. On PD 18, these rats were
singly placed in the testing chambers and baseline
locomotor activity was assessed for 15 min. Sham- andI
superior colliculus-lesioned rats were then injected with 
saline or U50,488 (5.0 mg/kg, ip) and returned to the
testing chambers for an additional 45 min.
Following behavioral testing, rats were returned to
their home cage and placed back with the dam. After an
48
additional 24 hr, rats were retested as described above,
except that half of the rats (counterbalanced for previous
drug treatment) were given a single injection of saline and
the other half an injection of NPA (0.01 mg/kg, ip).
Results
Histology
A representative lesion of the superior colliculus is
shown in Figure 7. Rats that did not have at least 75% of
i
the superior colliculus destroyed on each hemisphere were
removed from the experiment and replaced.
I
Body Weight !
The body weights of sham- and superior colliculus-
lesioned rats are shown in Figure 5 (middle panel). An
increase in body weight was evident in both sham- and
superior colliculus-lesioned rats, with no differences
being apparent between the two treatment groups [day main
effect, F(2, 52) = 123.30, p < 0.001] .
Locomotor Activity
Distance traveled (i.e., locomotor activity) data for
sham- and superior colliculus-lesioned rats given systemic
injections of U50,488 and NPA are presented in Figure 8. 
Systemic injections of 5.0 mg/kg U50,488 were again found
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Figure 7. Image of a thionin-stained section indicating 
the damage produced by an electrolytic lesion of the 
superior colliculus on postnatal day 16.
to increase the locomotor activity of 18-day-old rats
[agonist main effect, F(l, 6) = 29.50, p < 0.001; agonist x 
time interaction, F(8, 48) = 8.75, p < 0.001]. The
U50,488-induced locomotor activity exhibited by these rats
was diminished by bilateral lesions of the superior
colliculus [lesion x agonist x time interaction, F(8, 48) = 
2.79, p < 0.05] . More precisely, sham-lesioned rats given
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Figure 81 Mean distance traveled 1 (+SEM) of rats that had 
received sham or electrolytic lesions of the superior 
colliculus on postnatal day (PD) 16. On PD 18, rats (n = 
7) were injected with saline or U50,488 (5 mg/kg, ip) 15 
min into the behavioral testing session (indicated by the 
dashed line). On PD 19 the same fats were injected with 
saline or NPA (0.01 mg/kg, ip) 15 !min into the behavioral 
testing session (indicated by the ’dashed line) . (a)
Significantly different from the Sham-Saline group (open 
symbols). (b) Significantly different from the Lesion-
U50,488 group (filled square). ;
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IU50,488 had greater locomotor activity on time blocks 5-10
when compared to superior colliculus-lesioned rats given 
U50,488 (see upper graph, Figure 8). Lesioning the 
superior colliculus was not sufficient to block the 
locomotor activity induced by systemic injections of
I
U50,488, since the Lesion-U50,488 group was significantly
more active than saline controls (see Figure 8).
Therefore, superior colliculus lesions, like lesions of the
ventromedial thalamus, attenuated the locomotor activity
produced by systemic injections of U50,488.
In order to examine whether non-specific or incomplete
brain lesions affect the locomotor activity produced by
K-opioid receptor agonist, a correlational analysis examined
the relationship between lesion size and U50,488-induced
locomotor activity. A scatterplot1 representing the
relationship between lesion size and the distance traveled
scores of all lesioned-rats given systemic injections of 
U50-488 is shown on Figure 9. As predicted, the amount of
locomotor activity exhibited by rats treated with U50,488 
was negatively correlated with the amount of damage to the
superior colliculus (see Figure 9> [r(14) = -0.37]. Thus,
it is not likely that the reduction in locomotor activity
52
Superior Colliculus
Figure 9. Scatterplot representing the relationship 
between lesion size and distance traveled scores of U50- 
488-treated rats. Distance traveled scores were summated 
over the last 45 min of the testing session (i.e., the 
period beginning immediately after U50,488 was injected).
observed in superior colliculus-lesioned rats is a result 
of non-specific lesions to surrouniding brain areas.
I •
When the same rats were retested with saline or NPA 
. 1
(0.01 mg/kg, ip) on PD 19, both sham- and superior
colliculus-lesioned rats exhibited1 greater locomotor
activity on time blocks 5-10 when given NPA [agonist x time
interaction, F(8, 24) = 7.18, p < 0.001]. Lesioning the
superior colliculus did not disrupt NPA-induced locomotor
53
activity, because no differences between the Sham-NPA group
and the Lesion-NPA group were observed.
I
I
I
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CHAPTER EIGHT
EXPERIMENT THREE
Overview,
I
The first two experiments were conducted to determine
I
whether disruptions of the nigrothalamic and nigrotectali
ipathways attenuate U50,488- and NPA-induced locomotor
activity. The purpose of the third experiment was to
determine whether lesioning another brain region causes
non-specific reductions in U50,488Linduced locomotion.
Simply stated, Experiment 3 was conducted to provide an
anatomical control in which lesions to a particular brain
I
region were not expected to affect1 U5'0,488-induced
locomotor activity. To this end, rats were given sham ori
bilateral lesions of the nucleus accumbens and tested with
U50,488 and NPA on two consecutive days. It was expected
I
that lesions to the nucleus accumbens would not affect
U50,488-induced locomotor activity. However, because NPA-
induced locomotor activity is mediated via dopaminergic
mechanisms in the striatum and nucleus accumbens
(Kafetzopoulos, 1986; Kelly & Roberts, 1983), it was
hypothesized that lesions to the nucleus accumbens would
attenuate NPA-induced locomotor activity.
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Method
A total of 36 rats (n = 9 per group) received
bilateral electrolytic lesions or sham lesions of the
nucleus accumbens on PD 16. On PD, 18, these rats were
singly placed in the testing chambers and baseline
locomotor activity was assessed for 15 min. Sham- and
nucleus accumbens-lesioned rats were then injected with
saline or U50,488 (5.0 mg/kg, ip) and returned to the
testing chambers for an additional 45 min.
Following behavioral testing, rats were returned to
their home cage and placed back with the dam. After an
additional 24 hr, rats were retested as described above,
except that half of the rats (counterbalanced for previous
drug treatment) were given a single injection of saline and
I
the other half an injection of NPA (0.01 mg/kg, ip).
Results J
I
Histology ,
A representative lesion of the nucleus accumbens is
I
shown in Figure 10. Rats that did not have at least 50% of
the nucleus accumbens destroyed on each hemisphere were
removed from the experiment and replaced.
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i
i
I
i
i
Figure 10. Image of a thionin-stained section indicating 
the representative damaged produced by an electrolytic 
lesion of the nucleus accumbens on'postnatal day 16.
1 I
I
' I
Body Weight !
IThe body weights of sham- and!nucleus accumbens-
1 I
lesioned rats are shown in Figure 5 (right panel). All
I
rats showed a significant increase 1 in body weight across
i' ’ ,the four days of the experiment [day main effect, F(2, 52)
I
f
= 142.42,'p < 0.001]. In particular, sham- and nucleus
I
ii
: j
. i
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accumbens-lesioned rats exhibited similar body weight gain
during the experiment.
Locomotor Activity
Distance traveled (i.e, locomotor activity) data for
sham- and nucleus accumbens-lesioned rats given systemic
injections of U50,488 and NPA are presented in Figure 11.
Systemically administered U50,488 significantly enhanced
the locomotor activity of 18-day-old rats compared to 
saline controls [agonist main effect, F(l, 8) = 103.37, p <
I
0.001; agonist x time interaction, F(8, 64) = 6.35, p <
0.001]. Contrary to my predictions, bilateral lesions to
the nucleus accumbens disrupted the U50,488-induced
locomotor activity of 18-day-old rats [lesion x agonist
I
interaction, F(l, 8) = 7.31, p < 0^05; lesion x agonist x 
time interaction, F(8, 64) = 2.31, (p < 0.05] .
I
Specifically, the Sham-U50,488 group exhibited greater
activity on time blocks 6 and 8-12ithan rats in the Lesion-
I
U50,488 group (see upper graph, Figure 11). Lesioning the
nucleus accumbens, however, did not completely prevent
U50,488 from enhancing the locomotor activity of 18-day-old
rats, since the Lesion-U50,488 group was more active during
time blocks 5-12 compared to saline-treated rats (see
58
I
I
Figure ll'. Mean distance traveled !(±SEM) of rats that had 
received sham or electrolytic lesions of the nucleus 
accumbens'on postnatal day (PD) 16.1 On PD 18, rats (n = 7) 
were injected with saline or U50,48'8 (5 mg/kg, ip) 15 min 
into the behavioral testing session' (indicated by the 
dashed line) . On PD 19 the same ra'ts were injected with 
saline oriNPA (0.01 mg/kg, ip) 15 min into the behavioral 
testing session (indicated by the dashed line). (a)
Significantly different from the Sham-Saline group (open 
symbols). : (b) Significantly different from the Lesion- 
U50,488 group (filled square). j
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Figure 11) . Thus, like lesions of' the nucleus accumbens,
lesions of the ventromedial thalamus and superior
colliculus attenuated the U50,488-induced locomotor
activity of 18-day-old rats.
On PD 19, these same rats were injected with saline or
NPA (0.01 mg/kg, ip). Systemic injections of NPA produced
robust locomotor activity in both sham- and nucleus
accumbens-lesioned rats, with these differences reaching
statistical significance on time blocks 5-9 [agonist main
effect, F(l, 8) = 112.36, p < 0.00.1; agonist x time
interaction, F(8, 64) = 24.08, p <i 0.001]. Unexpectedly,
i
lesions of the nucleus accumbens did not affect the NPA-
induced locomotor activity of 19-day-old rats. This result
I
was surprising since the nucleus accumbens has substantial
numbers of dopamine receptors (Gelbard, Teicher, Faedda, &
Baldessarini, 1989; Rao, Molinoff,' & Joyce, 1991) and NPA's
effects are known to be mediated by dopamine receptors.
i
i
I
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CHAPTER NINE
DISCUSION,
I
Rationale'1
The purpose of the present study was to determine the
neuronal circuitry responsible for■K-opioid-mediated
locomotion in preweanling rats. Convincing evidence now
exists that systemic injections of U50,488 produces its
locomotor stimulating effects by activating K-opioid
receptors in the substantia nigra pars reticulata (Collins
et al., 2000). It is uncertain which nigral output pathway
is responsible for mediating the U50,488-induced locomotor
activity of preweanling rats, but it is possible that K-
opioid receptor stimulation enhances locomotion by
inhibiting GABAergic projections from the substantia nigra
pars reticulata to the ventromedial thalamus and superior
colliculus.
I
Nonontogenetic studies have provided the only evidence
that the nigrostriatal and nigrotectal pathways may be
important for K-opioid-mediated locomotion. Specifically,
although systemic administration of U50,488 does not
produce locomotor activity in adult rats (Jackson &' Cooper,
1988; Leyton & Stewart, 1992), unilateral microinjections
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of U50,488 into the substantia nigra pars reticulata
produces robust contralateral circling (Matsumoto et al.,
i
1988a). Importantly, lesions of the ventromedial thalamus
or superior colliculus attenuate U50,488-induced circling 
in adult rats (Thompson & Walker, i992). Therefore, in the 
present study, 16-day-old rats were given bilateral lesions
of the ventromedial thalamus (Experiment 1) or superior
colliculus (Experiment 2) followed, two days later (i.e.,
on PD 18) ', by a systemic injection, of U50,488. It was
I
predicted that bilateral lesions of the ventromedial
thalamus or superior colliculus would attenuate the
U50,488-induced locomotor activity of preweanling rats.
Role of the Ventromedial Thalamus and 
Superior Colliculus in U50,488-
and NPA-induced Locomotion
Systemic administration of U50,488 produced robust
I
locomotor activity in 18-day-old rats (see Figures 6, 8,
and 11). That U50,488 caused this behavioral effect was
not surprising, because systemic administration of U50,488
reliably increases the locomotor activity of preweanling
rats (Bolanos et al., 1996; Collins et al., 1998; Duke et
al. , 1997; Jackson & Kitchen, 1989; McDougall et al., 1997;
McLaughlin et al., 1995) . As expected, lesions to the
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ventromedial thalamus or superior colliculus significantly
; - i
decreased the U50,488-induced locomotor activity of 18-day-
i
old rats.; More specifically, rats[with bilateral lesions
[ ' ' I ‘ '
of the ventromedial thalamus or superior colliculus
! i! ■ .
exhibited an attenuated response to a systemic injection of
iU50,488 (see upper graphs, Figures[6 and 8). Importantly,
i ' ;
the same lesions did not disrupt the locomotor activity
produced by systemic injections of,the dopamine agonist NPA
i ■ . ‘ , i
(see lower graphs, Figures 6 and 8). Regardless of the
brain area lesioned (ventromedial thalamus or superior
i I ■ ' ' ■ ■colliculus), systemic injectipns of NPA stimulated the
locomotor activity of sham and lesioned rats in a similar
manner.
When, considered, together, it is apparent that the
, I
nigrothalamic and nigrotectal,pathways are part of an
integral bircuitry responsible.forithe ability of K-opioid-
i - . : ’ . ,
mediated locomotor activity of preweanling rat's. Moreover, 
i ■ ' / '
the functioning of non-opioid motor systems (i.e., those
systems mediating NPA-induced locomotion) were not affected
| . 1 ‘
by lesions of the ventromedial thalamus and superior
i 1
I
colliculus. This effect is important because.it reveals
Ithat ventromedial thalamus and superior colliculus lesions
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specifically disrupt the stimulatory actions of K-opioid
I
receptor agonists.
Lesions of the ventromedial thalamus or superior
colliculus alone were not capable of completely blocking
U50,488-induced locomotor activity: (see Figures 6 and 8).i
Several explanations may account for this effect. First,
I
it is possible that lesions of the', ventromedial thalamus
and superior colliculus were incomplete, thus allowing
U50,488-induced locomotor activity1to be expressed at a
Ireduced level. This explanation seems unlikely, however,
since care was taken to ensure that only animals with
complete lesions were included in the experiments. Second,
I
it is possible that both the ventromedial thalamus andI
superior colliculus are necessary for the full expression
of K-opioid-mediated locomotor activity. In other words,
when only one brain area was destroyed, the remaining non-
lesioned brain area (i.e., the ventromedial thalamus ori
superior colliculus) may have been sufficient to produce a
I
weakened, although significant, level of U50,488-induced
locomotor activity. Third, the inability of ventromedial
thalamus and superior colliculus lesions to completely
attenuate U50,488-induced locomotor activity, leaves open
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the possibility that other nigral output pathways (e.g.,
pathways projection to the striatum and pedunculopontine
nucleus) may mediate some of the behavioral effects induced
by K-opioid receptor agonists. This possibility cannot be
eliminated by the present study. In any event, it remains
certain that the nigrotectal and nigrothalamic pathways
mediate, at least partially, the locomotor activity
produced by K-opioid receptor agonists.
Role of the Nucleus Accumbens in 
U50,488-Induced Locomotion
For this study, it was important to determine the
specificity of lesion-induced effects. Thus, an additional
experiment was conducted to determine whether lesioning an
unrelated brain structure would reduce U50,488-induced
locomotion. The nucleus accumbens was the brain region
chosen as the anatomical control for two reasons. First,
lesioning the nucleus accumbens was not expected to affect
U50,488-induced locomotor activity, since U50,488's
locomotor activating effects are known to be mediated by
the substantia nigra pars reticulata (Collins et al.,
2000) . Second, lesioning the nucleus accumbens was
expected to disrupt NPA-induced locomotor activity, since
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NPA's actions are known to be mediated by the mesolimbic
pathway (Kafetzopoulos, 1986; Kelly & Roberts, 1983) . The
results from Experiment 3, however, suggest that I did not
choose an appropriate anatomical control.
Perhaps the most surprising finding was that the
nucleus accumbens lesions attenuated the U50,488-induced
locomotor activity of preweanling rats. More precisely,
rats with lesions to the nucleus accumbens exhibited a
decreased responsiveness to a systemic injection of U50,488
(see upper graph, Figure 11). These findings are
problematic because they complicate interpretation of data
from the other lesion experiments., Put another way,
because lesions of the nucleus accumbens, like lesions of
I
the ventromedial thalamus and superior colliculus,
attenuated U50,488-induced locomotor activity, it remains
possible that lesioning any brain region may reduce the
locomotor activity produced by K-opioid receptor
stimulation.
Even so, this explanation, that U50,488-induced
locomotor activity is attenuated by non-specific brain
lesions,,is unlikely for two reasons. First, there was a
strong correlation between U50,488-induced locomotor
66
activity and the amount of damage produced by superior
colliculus lesions (see Experiments 2 and Figure 9).
Moreover, lesions to the ventromedial thalamus and superior 
colliculus did not produce a global decrease in motor 
ability nor did they decrease NPA-induced activity. When
considered together, these findings provide strong evidence
that the ventromedial thalamus and' superior colliculus
mediate the stimulatory effects of K-opioid receptor
agonists and do not cause a general disruption of motor
functioning.
Second, there is evidence to .suggests that lesions of
the nucleus accumbens may indirectly affect the locomotor
stimulating effects of U50,488 by way of direct projections
to the substantia nigra pars reticulata. More precisely,
recent anatomical studies have demonstrated that the
nucleus accumbens provides input to cell bodies in
substantia nigra pars reticulata (Deniau, Menetrey, & 
Thierry, 1994; Montaron, Deniau, Menetrey, Glowinski, &
Thierry, 1996). This is important, because nucleus
accumbens lesions may have indirectly affected U50,488-
induced locomotor activity by altering the function of the 
nigrothalamic and nigrotectal pathways. Behavioral
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Ievidence for this explanation is available, since the
U50,488-induced locomotor activity-of preweanling rats is
decreased by dopamine receptor antagonist drugs (Duke et
al., 1997; Nazarian, Rodarte-Freeman, & McDougall, 1999).
When these results are considered ^together, it appears that
the nucleus accumbens may not have, been an appropriate
anatomical control for the present study, particularly
because the nucleus accumbens may be a component of the
circuitry mediating U50,488-induced locomotor activity.
I
Role of the Nucleus Accumbens in 
NPA-induced LocomotionI
Although lesions of the nucle.us accumbens were
effective in disrupting U50,488-induced activity, the same
lesions did not disrupt the locomo’tor activating effects of
NPA (see lower graph, Figure 11). This finding was
unexpected because the nucleus acc/umbens has a substantial
number of dopamine receptors that are evident as early as
the first postnatal week (Gelbard et al., 1989; Rao et al.,
1991). Moreover, lesions to the nucleus accumbens have
been shown to disrupt the NPA-induced locomotor activity of
adult rats (Kafetzopoulos, 1986; Kelly & Roberts, 1983). 
Importantly, adult and preweanling rats do not demonstrate 
a qualitatively different behavioral profile after systemic
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administration of NPA, as.both age'groups show marked 
increases in locomotor activity after NPA treatment (Duke
et al., 1997; McDougall, Crawford, 1 & Nonneman, 1992;
i
Mestlin & McDougall, 1993). Consequently, it was
reasonable to expect that nucleus accumbens lesions would
I
affect the NPA-induced locomotor activity of preweanling
and adult rats similarly.
At least two explanations may account for the 
inability of nucleus accumbens lesions to disrupt NPA-
induced activity. First, it is possible that lesions of
the nucleus accumbens were not complete enough to disrupt 
the locomotor enhancing effects of' NPA, since complete 
lesions of the nucleus accumbens are necessary to disrupt
the behavior of adult rats (Kafetzopoulos, 1986; Kelly &
Roberts, 1983). In the present study, histological results
revealed that many of the rats included in the analyses had
only partial lesions («50%) of the nucleus accumbens. Thus,
the extent of nucleus accumbens damage may have been
insufficient to disrupt the NPA-induced locomotor activity
of preweanling rats.
Second, it is possible that surviving regions of the
nucleus accumbens or striatum may have compensated for the
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loss of dopaminergic activity. Consistent with this
hypothesis are studies showing that neurochemical and
behavioral deficits are only evident when more than 95% of, I
dopamine cell bodies are destroyed (for a review, see
Robinson, Castaneda, & Whishaw, 1990). Moreover,
extracellular concentrations of dopamine remain unaffected
(i.e., are within normal control levels) even when 80% of
dopamine neurons in the substantia nigra are lesioned
(Castaneda, Whishaw, & Robinson, 1,990) . These findings may
be the result of compensatory changes by the remaining
I
population of dopamine neurons, including, but not limitedI
to, increased dopamine synthesis and release. Similar
compensatory changes in dopaminergic activity may account
for the lack of behavioral deficits exhibited by 6-
hydroxydopamine-treated rats given systemic injections of a
dopamine agonist. For instance, amphetamine-induced
locomotion and rearing are not disrupted until dopamine
depletion reaches 95% (Castaneda et al., 1990; Robinson et
al., 1990). In light of these findings, it is plausible
that compensatory changes in dopaminergic activity may have
allowed for the expression of NPA-induced locomotor
activity!in preweanling rats.
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I . 'Conclusion
i !The present study has demonstrated that the locomotor
i i
activity produced by systemic administration of U50,488 is,
at least partially, mediated by the ventromedial thalamus
and superior colliculus. This conclusion is supported by! '
I > I
results showing that: (a) lesions to the ventromedial
I ' ' 1
thalamus land superior colliculus attenuate U50,488-induced■ 1
locomotor activity, and (b) the same lesions fail to
'! I '
disrupt the locomotor activity produced by systemic
I 1 ' .
i 1injections of NPA. The specificity of these lesion-induced 
effects i's somewhat ambiguous, because nucleus accumbens
I 1
i • 1lesions also attenuated the locomotor activity of U50,488-
' ‘ i* -J
treated rjats. The latter finding is difficult to
! : ; -
interpret!, since the nucleus accumbens may indirectly
■ i
affect th!e activity of the ventromedial thalamus. At
I
present, therefore, the most parsimonious conclusion is 
that the ventromedial thalamus and.superior colliculus areT
!
the primary output structures mediating the U50,488-induced
i
locomotor activity of preweanling rats. Future research
l
will be heeded to determine whether the mesolimbic dopamine
pathway i s also important for K-opioid-mediated locomotion.
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